June 9, 2020 -- SwiftScale Biologics said it has used its rapid biologics manufacturing platform to manufacture a COVID-19 neutralizing antibody candidate at clinical scale.
Designed to reduce biologics development time by several months in comparison with traditional manufacturing platforms, SwiftScale's platform leverages synthetic biology techniques and unique strains to produce high yields of therapeutics in their physiological and functional forms at large scale, according to the firm. SwiftScale said that it's in the process of reaching a production capacity of 100,000 doses per month under good manufacturing practices specifications.